Project Grant F31DA063333

Award Date 9/30/25
Completion Date 6/30/28
Dollars Obligated $84K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This Project Grant award of $2,811,343, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the "Center for Genetics, Genomics, and Epigenetics of Substance Use Disorders in Outbred Rats" at the University of California, San Diego (UCSD). The award will fund critical core services to maintain two heterogeneous stock (HS) rat breeding colonies and provide genotyping, data analysis, and pilot project support...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will support a $346,911 cross-species research study to identify early life environmental and genetic risk factors for substance use disorders (SUDs). The key objectives are to: 1) determine how early life environment influences neurocognitive development and its relationship to adult impulsivity behaviors; 2) identify genomic networks associated...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $944,888 to Seattle Children's Hospital (dba Seattle Children's Research Institute) to conduct a deep analysis of the transcriptome in rats to understand the genetics of substance use disorders (SUDs). The 5-year project aims to expand integrative genome and transcriptome analysis to study a wide range of transcriptional phenotypes,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to develop a translational rat model of the neonatal intensive care unit (NICU) experience and its impacts on substance use disorder risk. The $368,315 award to the Georgia State University Research Foundation will: 1) design and test a model combining early pain, resource scarcity, and separation from caregivers to mimic key aspects of...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $272,395 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the biochemical mechanisms of the G9A/GLP histone methyltransferases and their role in the development of addictive behaviors. The key objectives of this 2-year award, which runs from April 2025 to March 2027, are to: 1) identify specific...
This $2,419,326 Project Grant awarded by the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a longitudinal study to investigate neurobehavioral and psychosocial predictors of health risk behaviors (HRBs) in adolescence and young adulthood. The primary awardee, Virginia Polytechnic Institute & State University, will conduct assessments over 15 years to understand brain development and its impact on substance use and...
This federal Project Grant award of $476,123.00 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant aims to leverage machine learning and genomic technologies to investigate how genetic variants associated with substance use disorders and sleep phenotypes may impact the circadian regulation of gene expression. The research will be conducted by Carnegie Mellon University and involves several key activities:...
This federal Project Grant award of $357,613 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to identify novel rare and common genetic variants associated with substance use disorders (SUDs) and enhance disease prediction through a whole-genome multi-ancestry polygenic risk score framework. The research, conducted by Yale University, aims to leverage large-scale whole-genome sequencing datasets to address...
This $234,000 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research at Oregon Health & Science University (OHSU) to investigate rapid protein translation in nucleus accumbens neurons in response to a cocaine-associated cue. The goal is to use translating ribosome affinity purification and RNA sequencing (TRAP-seq) to identify mRNAs that are actively translating during re-exposure to cocaine...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $438,750 to the University of California, San Diego (UCSD) to investigate pre-existing differences in GABAergic and glutamatergic transmission within the central amygdala and their potential contribution to individual differences in cocaine addiction susceptibility. The study aims to characterize and compare basal GABAergic and...

UNRAVELING THE ROLE OF TANDEM REPEATS AND STRUCTURAL VARIANTS IN ADDICTION-RELATED BEHAVIORS USING HETEROGENEOUS STOCK RATS - PROJECT ABSTRACT DRUG ABUSE IS A SIGNIFICANT PUBLIC HEALTH CRISIS, WITH OVER 106,000 DRUG-INVOLVED OVERDOSE DEATHS IN THE U.S. IN 2021. HUMAN GENOME-WIDE ASSOCIATION STUDIES (GWAS) HAVE STARTED TO IDENTIFY UNDERLYING CAUSAL GENETIC LOCI IN ADDICTION, BUT MOST OF THEM SACRIFICE PHENOTYPIC GRANULARITY IN ORDER TO OBTAIN LARGER SAMPLE SIZES. GWAS IN MODEL ORGANISMS SUCH AS N/NIH HETEROGENEOUS STOCK (HS) RATS PROVIDE A VALUABLE ALTERNATIVE THAT BRIDGES THIS GAP. HOWEVER, DETERMINING THE CAUSAL GENES OF ADDICTION REMAINS CHALLENGING BECAUSE MOST GWAS STUDIES FOCUS ON SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) AND OVERLOOK COMPLEX VARIANTS SUCH AS AND TANDEM REPEATS (TRS) AND STRUCTURAL VARIANTS (SVS). TRS AND SVS ARE LONGER GENOME ALTERATIONS COMPARED TO SNPS, WHICH MAKES THEM HARD TO DETECT WITH SHORT-READ SEQUENCING. THIS PROJECT PROPOSES TO ADDRESS THIS SERIOUS LIMITATION BY USING CUTTING-EDGE LONG READS SEQUENCE TO DISCOVER AND GENOTYPE TRS AND SVS IN SUPPORT TO INVESTIGATE THEIR ROLES IN DRUG ABUSE USING HS RATS. THE CENTRAL HYPOTHESIS IS THAT TRS AND SVS CONTRIBUTE TO THE VARIABILITY IN GENE EXPRESSION, HENCE, AFFECTING ADDICTION-RELATED BEHAVIORS IN HS RATS. IN AIM 1, THE TRS AND SVS LANDSCAPE IN HS RATS WILL BE CHARACTERIZED USING NEWLY GENERATED LONG READS IN BOTH INBRED HS FOUNDERS AND OUTBRED HS RATS. THEN, IN AIM 2, A COMPUTATIONAL PACKAGE WILL BE DEVELOPED TO IMPUTE TRS AND SVS TO THE WHOLE POPULATION OF OVER 20 THOUSAND OUTBRED HS RATS. FINALLY, IN AIM 3, QUANTITATIVE TRAIT LOCI MAPPING ANALYSIS WILL BE PERFORMED TO LINK TRS AND SVS TO GENE EXPRESSION AND ADDICTION-RELATED BEHAVIORAL TRAITS. THIS INNOVATIVE APPROACH INTEGRATING LONG-READ SEQUENCES FOCUSES ON UNDERREPRESENTED GENETIC VARIANTS, PROVIDING NEW INSIGHTS INTO ADDICTION GENETICS AND POTENTIALLY UNCOVERING NOVEL GENETIC MECHANISMS INFLUENCING ADDICTION-RELATED BEHAVIORS. COMPLETION OF THIS PROJECT WILL NOT ONLY PROVIDE WITH THE APPLICANT WITH VALUABLE TRAINING IN BEHAVIORAL GENETICS AND BIOINFORMATICS AND LEAD TO POTENTIAL THERAPEUTIC TARGETS AND STRATEGIES FOR PREVENTING AND TREATING DRUG ABUSE, BUT ALSO CREATE A COMMUNITY RESOURCE THAT WILL ENHANCE ONGOING RAT GENETIC STUDIES.

Posted 4/1/25, 12:00 AM